B007
Small molecule
B007 is one of 89 small molecule programs targeting Pemphigus. It is currently in development.
3
Indications
4
Total Trials
4
Active Trials
88
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
102 competitors in Myasthenia Gravis
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Ultomiris
AstraZenecaPhase 3
Vyvgart
ArgenxPhase 3
Cellcept
RochePhase 3
Soliris
AstraZenecaPhase 3
Zilbrysq
UCBPhase 3
Fabhalta
Johnson & JohnsonPhase 3
Arava
SanofiPhase 3
ENSPRYNG
RochePhase 3
Rhapsido
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Membranous Nephropathy2 trials
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
Recruiting·SShanghai Jiaolian Drug Research and Development Co., Ltd·Phase 2/3·NCT06470191·216 enrolled
Myasthenia Gravis1 trial
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
Recruiting·SShanghai Jiaolian Drug Research and Development Co., Ltd·Phase 2/3·NCT06447597·104 enrolled
Pemphigus1 trial
A Clinical Study of B007 in the Treatment of Pemphigus.
Recruiting·SShanghai Jiaolian Drug Research and Development Co., Ltd·Phase 2/3·NCT06454357·132 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for B007. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]